WCN26-8313 ABSOLUTE PROTEINURIA OVER TIME WITH NEFECON VS PLACEBO IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY: RESULTS FROM THE PHASE 3 NEFIGARD TRIAL

Read full text Summarise with VIRAT
Authors: Heather N. Reich, Brad H. Rovin, Richard A. Lafayette, Russell Jones, Jonathan Barratt
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Proteinuria reduction is a surrogate marker of immunoglobulin A nephropathy (IgAN) treatment effectiveness. The Kidney Disease: Improving Global Outcomes (KDIGO) 2025 guidelines for IgAN recommend absolute proteinuria of

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Chronic Kidney Disease and Diabetes Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106314–106314
Publication date
25 March 2026
Language
EN